Xencor, Inc.
NASDAQ:XNCRBiotechnology
Healthcare
$34.01 -1.03%
-$0.13 today
- Market cap
- $2.55B
- Beta
- 0.93
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$2.29
52W Low $6.92High $18.69
Volume 1.09M
Average 0.80M
Income Statement
Follow revenue through to earnings.
Revenue
$125.58M
FY 2025 · Annual
+13.7% YoYOperating Income
-$177.50M
FY 2025 · Annual
Net Income
-$91.92M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 275.11M | 164.58M | 174.62M | 110.49M | 125.58M |
| Cost of Revenue | 192.51M | 199.56M | 0 | 227.69M | 10.51M |
| Gross Profit | 82.6M | (34.98M) | 174.62M | (117.19M) | 115.06M |
| Gross Margin | 30.0% | -21.3% | 100.0% | -106.1% | 91.6% |
| Research & Development | 192.51M | 199.56M | 253.6M | 227.69M | 239.43M |
| Selling, General & Admin | 38.84M | 47.49M | 53.38M | 58.89M | 63.64M |
| Operating Expenses | 38.84M | 47.49M | 306.98M | 61.22M | 292.57M |
| Depreciation & Amortization | 7.49M | 8.8M | 11.5M | 12.11M | 10.51M |
| EBITDA | 90.14M | (45.7M) | (101.96M) | (186.17M) | (46.98M) |
| EBITDA Margin | 32.8% | -27.8% | -58.4% | -168.5% | -37.4% |
| Operating Income | 43.77M | (82.47M) | (132.36M) | (178.41M) | (177.5M) |
| Operating Margin | 15.9% | -50.1% | -75.8% | -161.5% | -141.4% |
| Interest Income | 862K | 4.82M | 18.63M | 31.93M | 27.52M |
| Interest Expense | 13K | 0 | 0 | 36.64M | 31.93M |
| Other Income / Expenses | 38.86M | 27.97M | 12.73M | (56.52M) | 87.87M |
| Income Before Tax | 82.63M | (54.51M) | (119.63M) | (234.92M) | (89.42M) |
| Pre-Tax Margin | 30.0% | -33.1% | -68.5% | -212.6% | -71.2% |
| Income Tax Expense | 0 | 673K | 13.66M | 1.62M | 2.5M |
| Net Income | 82.63M | (55.18M) | (133.13M) | (232.62M) | (91.92M) |
| Net Margin | 30.0% | -33.5% | -76.2% | -210.5% | -73.2% |
| EPS (Basic) | 1.42 | (0.93) | (2.08) | (3.58) | (1.24) |
| EPS (Diluted) | 1.37 | (0.93) | (2.08) | (3.58) | (1.24) |
| 58.38M | 59.65M | 60.5M | 65.04M | 74.24M | |
| 60.5M | 59.65M | 60.5M | 65.04M | 74.24M |
XNCR Earnings Waterfall · TTM
NASDAQ:XNCR · Revenue to Net Income
Key Ratios
EPS$-2.17
Gross Margin18.8%
Net Margin-737.3%
P/E Ratio-23.7
P/S Ratio76.7
Analysis
$105.0M of revenue converted into -$163.3M of net income for the selected period. Gross margin is 18.8% and net margin is -737.3%, showing how much revenue survives after costs and taxes. EPS is $-2.17, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 |
How much revenue does XNCR generate?
Xencor, Inc. (XNCR) reported $125.58M of revenue in fiscal 2025.
Is XNCR profitable?
Xencor, Inc. (XNCR) reported -$91.92M of net income, with a net margin of -73.2%.
Continue the stock analysis
Jump to another research area for this company.